Skip to content
OpenCapital
Get started

Organon OGN Follistim AQ — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Biogen logo
BIIBQALSODY — Total Revenue
$32.5M+110%
The Cooper Companies, Inc. logo
COOFertility — Net Sales
$143.8M+13.3%
Biogen logo
BIIBFAMPYRA — Total Revenue
$0-100%
Vertex Pharmaceuticals logo
VRTXALYFTREK — Product revenues, net
$424.4M+687%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$555M+16.1%
Biogen logo
BIIBFumarate — Total Revenue
$288.5M-16.4%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's follistim aq — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's follistim AQ — revenue?
Organon (OGN) reported follistim AQ — revenue of $61M in Q1 2026.
How has Organon's follistim AQ — revenue changed year-over-year?
Organon's follistim AQ — revenue decreased by 11.6% year-over-year, from $69M to $61M.
What is the long-term trend for Organon's follistim AQ — revenue?
Over 4 years (2021 to 2025), Organon's follistim AQ — revenue has grown at a 2.8% compound annual growth rate (CAGR), from $237M to $265M.
What does follistim AQ — revenue mean?
This metric represents the total gross sales generated from the Follistim AQ product line, a key therapeutic solution within the company's women's health portfolio. It reflects the market demand and commercial performance of this specific fertility treatment across global markets. Tracking this revenue stream provides insight into the company's ability to maintain its competitive position in the specialized reproductive health sector.